New MS Drug Approved “Kesimpta” by Novartis

The first self-administered, targeted B-cell treatment for relapsing multiple sclerosis (MS) received FDA approval on Thursday, Novartis announced. Ofatumumab (Kesimpta), an antibody targeting CD20-positive B cells, is approved for adult patients with clinically...